论文部分内容阅读
目的：树突状细胞（DC）是一种重要的抗原递呈细胞，在T细胞参与的HLA限制性免疫应答中起重要作用。已证实在动物模型中DC递呈抗原可以诱导出T细胞介导的免疫反应。我们在体外扩增获得肿瘤患者DC，观察其特点，并以MAGE－3／CEA（HLA－A2／A24＋）肽疫苗冲击DC诱导特异性CTL，研究其杀伤活性。方法：选择MAGE－3－HLA－A2／A24＋或CEA－HLA－A24＋肿瘤患者，收集PBMNC中的贴壁细胞，在含有rhGM－CSF、rhIL－4的1640中培养诱导DC细胞，第7天加入HLA－A2－MAGE－3、HLA－A24－MAGE－3、HLA－A24－CEA肽冲击。以肽冲击后的DC与未经纯化的T细胞混合培养（T－DC－P）诱导的CTL作为效应细胞，Mel526，803，Raji，K562作为靶细胞，以LDH法检测特异性CTL的杀伤力。结果：体外扩增可获得高纯度的DC，高表达DC特异性表面标志CD40（74．18％±15．76％）、CD86（94．6％±3．80％）、HLA－DR（88．6％±10．94％）。不同肿瘤患者DC得率表现出较大差异（7．07％±3．24％），反映出免疫功能的不同。T－IL－2细胞与T－DC－P细胞对Mel526和803细胞株的杀伤活性有显著性差异（P＜0．01），可以将特异性杀伤力提高25％～35％，而对Raji和K562细胞株的杀伤活性无显著性差异（P＞0．01）。结论：rhGM－CSF、rhIL－4体外联?
Purpose: Dendritic cells (DCs) are an important antigen-presenting cell and play an important role in the HLA-restricted immune response in which T cells participate. DC-presenting antigens have been shown to induce T cell-mediated immune responses in animal models. We obtained DCs from patients with tumors in vitro and observed their characteristics. We used DCs induced by MAGE-3/CEA (HLA-A2/A24+) peptide vaccines to induce specific CTLs and study their killing activity. METHODS: MAGE-3-HLA-A2/A24+ or CEA-HLA-A24+ tumor patients were selected and adherent cells in PBMNC were collected. DCs were induced in 1640 containing rhGM-CSF and rhIL-4, and they were added on the 7th day. Impact of HLA-A2-MAGE-3, HLA-A24-MAGE-3, HLA-A24-CEA peptides. Peptide-pulsed DCs and unpurified T-cell mixed cultures (T-DC-P)-induced CTLs were used as effector cells. Mel526, 803, Raji, and K562 were used as target cells. Specific LTL assay was used to detect the lethality of specific CTLs. . RESULTS: High purity DCs could be obtained by in vitro expansion, with high expression of DC-specific surface markers CD40 (74.18% ± 15.76%), CD86 (94.6% ± 3.80%), and HLA-DR (88%). .6% ± 10.94%). The DC yield of different tumor patients showed a large difference (7.07% ± 3.24%), reflecting the different immune function. The killing activity of T-IL-2 cells and T-DC-P cells on Mel526 and 803 cell lines was significantly different (P<0.01), and the specific lethality could be increased by 25% to 35%, compared to Raji. There was no significant difference in killing activity between K562 and K562 cell lines (P>0.01). Conclusion: rhGM-CSF, rhIL-4 in vitro combination?